Navigation Links
China Botanic Attends 2012 Trade Fair

HARBIN, China, July 12, 2012 /PRNewswire-Asia/ -- China Botanic Pharmaceutical Inc. (NYSE AMEX: CBP) ("China Botanic" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and Traditional Chinese Medicines ("TCM") in China, today announced that on June 28, 2012 the Company attended the 47th session of the National New and Special Medicine Trade Fair (the "Trade Fair"), held in Qingdao, Shandong province.

The Trade Fair attracted more than 1,500 pharmaceutical companies and 70,000 visitors from around the world. At the Trade Fair, China Botanic exhibited a wide a range of products, including Siberian Ginseng Extract, Ginseng and Venison Extract, Banlangen Granules, Tianma Tablets, Compound Honeysuckle Granules, Shengmai Granules, Siberian Ginseng Tablet, and Badger Oil. The Company received a positive response from participants at the Trade Fair and has signed two Letters of Intent valued at approximately RMB2.8 million (US$0.4 million).

"We have received positive responses from participants at the Trade Fair. This event provides a great opportunity to market our products to players from China's pharmaceutical industry and increase awareness of our products and improve our corporate visibility," commented Mr. Shaoming Li, Chairman and Chief Executive Officer of China Botanic. "We are committed to participating in industry events which we believe help expand our market presence, brand recognition and drive revenue growth."

For more information on the Event, please visit

ABOUT CHINA BOTANIC PHARMACEUTICAL INCChina Botanic Pharmaceutical Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in the People's Republic of China. All of the Company's products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China. For more information, please visit

Safe Harbor StatementThis press release contains certain statements that may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management's beliefs, assumptions and expectations of the Company's future operations and financial performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Company's ability to manage expansion of its operations effectively, and other factors detailed in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.Company Contact:CCG Investor Relations:China Botanic Pharmaceutical Inc.

Mr. Mark Collinson, PartnerMs. Portia Tan, IR Contact

Phone: +1-310-954-1343 (Los Angeles)Tel: 86-451-8260-2162

Email: mark.collinson@ccgir.comEmail:


SOURCE China Botanic Pharmaceutical Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. The 2nd Pharma Logistics China 2012 to be Held in Shanghai on 21-22 August
2. China Pharmaceuticals and Healthcare Report Q3 2012
3. China Botanics Siberian Ginseng Extract Recognized as Safe Medicine
4. Biosimilars in Emerging Economies - Advanced Recombinant Technology Platforms and Low Cost Manufacturing Put India and China at a Strategic Advantage in Biosimilar Production
5. Diabetes Care Devices in Emerging Countries (China, India, Brazil) to 2017 - Greater Awareness is Increasing Demand for Self-Monitoring of Blood Glucose (SMBG) in the Home Care Segment
6. China ENT Devices Market Outlook to 2018 - Diagnostic Devices, Hearing Aid Devices, Hearing Implants and Others
7. The Pharmaceutical Market: China
8. China Biologic Receives SFDA Manufacturing Approval Certificate for Human Coagulation Factor VIII
9. TaiGen Biotechnology Out-Licensed China Rights of Novel Antibiotic, Nemonoxacin, to Zhejiang Medicine
10. China Botanic Schedules Conference Call to Discuss Second Quarter Fiscal Year 2012 Results
11. BHR Pharma Expands SyNAPSe® Trial into Thailand, China and Russia
Post Your Comments:
(Date:11/30/2015)... 2015   Royal Philips  (NYSE: PHG ... Radiology Solutions, a fully integrated, consultative approach to ... data-driven practice management approaches that combine imaging systems, ... improve care delivery and reduce costs. Making its ... North America Annual Meeting (RSNA) in ...
(Date:11/30/2015)... -- global cell culture market is expected to ... by 2022 at a CAGR of 7.1% therein. --> ... 2013 value of US$6.1 bn to US$11.3 bn by 2022 at ... has announced the release of a new market research study, detailing ... Culture Market - Global Industry Analysis, Size, Share, Growth, Trends and ...
(Date:11/30/2015)... , Nov. 30, 2015   Royal Philips ... Implant, the industry,s first MRI guided user interface and ... of patients with MR Conditional implants, such as knee ... 2015 Radiological Society of North America Annual Meeting ... and supports diagnostic confidence of this growing patient population. ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... 30, 2015 , ... Until now, the St. Louis Fetal Care Institute ... of Myelomeningocele Study) trial. One of these exclusion criteria was a BMI above 34.9. ... to 24.9 is considered normal, 25 - 29.9 is overweight and above 30 is ...
(Date:11/30/2015)... ... November 30, 2015 , ... Thermi™, a world ... announce that its ThermiRFR temperature controlled radiofrequency platform has received CE marking and ... platform which uses temperature as a clinical endpoint. The technology has been ...
(Date:11/30/2015)... ... November 30, 2015 , ... The world of hair transplants and restoration is ... These techniques and procedures have been in use for many years and are among ... Parsa Mohebi, M.D. has utilized many of these methods over the years, he also ...
(Date:11/30/2015)... ... November 30, 2015 , ... The presidential race normally ... styling. So why is it a national news story when Donald Trump makes disparaging ... M.D., because appearances count more than anyone wants to admit when it comes to ...
(Date:11/30/2015)... , ... November 30, 2015 , ... According to Los ... people to overeat are not necessarily caused by real hunger, but instead by ... needs food. He notes that, while many patients are aware that weight loss surgery ...
Breaking Medicine News(10 mins):